Momelotinib

Drug Profile

Momelotinib

Alternative Names: CYT-387; GS-0387; Momelotinib dihydrochloride

Latest Information Update: 20 Jul 2017

Price : $50

At a glance

  • Originator Cytopia Research
  • Developer Gilead Sciences
  • Class Antineoplastics; Benzamides; Morpholines; Pyrimidines; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myeloproliferative disorders
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Essential thrombocythaemia; Myelofibrosis; Myeloproliferative disorders; Pancreatic cancer; Polycythaemia vera
  • Phase I Non-small cell lung cancer

Most Recent Events

  • 02 Jun 2017 Updated adverse events data from the SIMPLIFY-1 phase III trial in Myelofibrosis, essential thrombocythaemia and polycythaemia vera presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 17 Apr 2017 Gilead Sciences terminates a phase-I trials in Pancreatic cancer (Combination therapy, Late-stage disease, Second-line therapy or greater; Treatment-resistant) in USA (NCT02244489)
  • 24 Mar 2017 Gilead Sciences terminates phase I trial in Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Metastatic disease) in USA (NCT02258607)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top